Two biosimilars of Eli Lilly’s blockbuster osteoporosis treatment ... Forsteo (teriparatide) – a bone-building parathyroid hormone drug sold as Forteo in the US – has been a big earner ...

This case study explains how Eli Lilly, the pharmaceuticals company, promoted its 'Forteo' treatment for osteoporosis in Japan, despite barriers including a ban on advertising directly to patients.

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.72 billion and ...